• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Transfusion . Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations

tetano

Editor, Senior Moderator
Transfusion


. 2020 Sep 25.
doi: 10.1111/trf.16119. Online ahead of print.
Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations


Christof Jungbauer[SUP] 1 [/SUP], Lukas Weseslindtner[SUP] 2 [/SUP], Lisa Weidner[SUP] 1 [/SUP], Simon G?nsdorfer[SUP] 1 [/SUP], Maria R Farcet[SUP] 3 [/SUP], Eva Gschaider-Reichhart[SUP] 3 [/SUP], Thomas R Kreil[SUP] 3 [/SUP]



Affiliations

Abstract

Background: Transfusion of SARS-CoV-2 convalescent plasma is a promising treatment for severe COVID-19 cases, with success of the intervention based on neutralizing antibody content. Measurement by serological correlates without biocontainment needs, and an understanding of donor characteristics that may allow for targeting of more potent donors would greatly facilitate effective collection.
Study design and methods: One hundred convalescent plasma units were characterized for functionally active SARS-CoV-2 neutralizing antibodies, as well as for SARS-CoV-2 binding antibodies, with the intention to establish a correlation between the functionally more relevant neutralization assay and the more accessible ELISA. Donor demographics such as COVID-19 disease severity, age and sex were correlated with antibody titers.
Results: A mean neutralization titer 50% of 1:230 (range < 1:8 - 1:1765) was seen for the 100 convalescent plasma units, with highly significant (p < 0.0001), yet quantitatively limited (R[SUP]2[/SUP] = 0.2830) correlation with results of the ELISA. Exclusion of units with particularly high titers (>1:500) from analysis improved correlation (R[SUP]2[/SUP] = 0.5386). A tendency of higher titer plasma units from donors with increased disease severity, advanced age and of male sex was seen, yet the functional relevance of this difference is questionable.
Conclusion: The ELISA-based correlation to neutralization titer enabled a threshold proposal that could be used to eliminate lower titer units from the clinical supply for COVID-19 treatment. Disease severity may be associated with the development of higher titers of neutralizing antibodies, although larger case numbers will be needed for additional confirmation. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; ELISA correlation; Severe acute respiratory syndrome Coronavirus 2; convalescent donor selection; virus neutralization.
 
Back
Top Bottom